The quest to combat chronic kidney inflammation has taken an intriguing turn with a recent discovery by Mayo Clinic researchers. Their innovative approach involves a combination therapy of dasatanib, a cancer drug, and quercetin, a naturally occurring substance, to target the harmful effects of senescent cells, or as they're colloquially known, "zombie cells," in diabetic kidney disease. This strategy, published in eBioMedicine, a Lancet publication, offers a glimmer of hope for the more than 12 million Americans affected by this condition, which is the leading cause of kidney failure.
Dr. LaTonya Hickson, the study's principal investigator and a nephrologist at Mayo Clinic, emphasizes the significance of this finding: "Our study revealed that this combination therapy, administered over a short period, successfully reduced the abundance of senescent cells and improved kidney function in a preclinical model of diabetic kidney disease."
The focus on senescent cells is not without reason. These cells, which fail to undergo natural death, linger in tissues, contributing to aging and disease. The treatment approach, known as senolytics, involves using natural and designed substances to selectively target and eliminate these cells. In a previous pilot clinical trial, Dr. Hickson and her team found that the combination of dasatanib and quercetin reduced senescent cells in skin and fat tissues of patients with diabetic kidney disease.
What makes this study particularly fascinating is the non-invasive nature of the treatment. Dr. Xiaohui Bian, a nephrologist and lead author of the study, explains, "It was crucial to demonstrate the impact of this short-course treatment on the kidneys without subjecting patients to invasive procedures."
In a preclinical model, the team observed that the combination therapy improved kidney function, reduced injury, and decreased senescent cells and inflammation. Additionally, in cultured human kidney cells, the therapy reduced the abundance of senescent cells and their inflammatory response.
Dr. Hickson concludes, "The results indicate that this combination treatment has the potential to mitigate and halt kidney damage caused by diabetes. The promising findings from these investigations suggest that larger-scale studies using senolytics should be pursued to enhance kidney health in patients."
This innovative approach to tackling diabetic kidney disease offers a new perspective on the potential of targeted therapies. While more research is needed, the initial findings provide a glimmer of hope for those affected by this debilitating condition.
